Dihexa: research, legal status and who sells it
This page is information, not medical advice. Dihexa is not approved as a medicine in the markets below unless stated. We don't publish dosing or usage instructions.
- Also known as
- Dihexa acetate, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
- Category
- Angiotensin IV-derived synthetic peptide analogue
- Evidence level
- Preclinical (lab and animal studies)
- Price range
- $8.41/mg to $28.00/mg, median $18.80/mg across 5 vendors (compare)
- Our lab tests
- None yet (how testing will work)
Legal and regulatory status
| Where | Status |
|---|---|
| United States | Not FDA-approved; the compounding nomination for dihexa acetate was withdrawn after FDA found no human exposure data, and FDA plans to consult its advisory committee on it before the end of February 2027 [1][2][3]. |
| United Kingdom | No UK-licensed medicine containing dihexa appears in the MHRA products database [4]. |
| European Union | No medicine containing dihexa is authorized in the EU, according to EMA's central and Article 57 product data [5][6]. |
| Canada | No product containing dihexa appears in Health Canada's Drug Product Database [7]. |
| Australia | Dihexa is not named in Australia's Poisons Standard (October 2026) [8]. |
| Sport (WADA) | Not named on the 2026 Prohibited List. Section S2 bans hepatocyte growth factor (HGF) and growth factor modulators, and section S0 bans other pharmacological substances with no current approval for human therapeutic use [9]; a lab study found that dihexa binds HGF and boosts its activity [10]. |
We haven't published a full overview of Dihexa yet. The legal status table and live prices on this page are current.
Dihexa prices: cheapest listings
The five lowest $/mg listings out of 6. See all Dihexa prices
| Vendor | Transparency | Product | Size | Price | $/mg | Stock | Vendor's page |
|---|---|---|---|---|---|---|---|
| Volta Peptides | 70 | 10 mg | $84 | $8.40/mg | Out of stock | View | |
| PurePeps | 35 | 10 mg | A$120 | $8.41/mg | View | ||
| Modern Aminos | 77 | 5 mg | $94 | $18.80/mg | View | ||
| Nationwide Peptides | 85 | 10 mg | $200 | $20.00/mg | Out of stock | View | |
| Nationwide Peptides | 85 | 5 mg | $100 | $20.00/mg | Out of stock | View |
Sources
- Drugs@FDA: FDA-Approved Drugs (database searched by active ingredient). U.S. Food and Drug Administration. Accessed Oct 14, 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). U.S. Food and Drug Administration. Accessed Oct 14, 2026
- Meeting of the Pharmacy Compounding Advisory Committee (to be held before the end of February 2027). U.S. Food and Drug Administration. Accessed Oct 14, 2026
- MHRA Products: licensed-medicine search for "dihexa". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
- EMA medicines data: centrally authorised human medicines (export of 14 October 2026). European Medicines Agency. Accessed Oct 14, 2026
- EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 14, 2026
- Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 14, 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 14, 2026
- World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 14, 2026
- The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. Journal of Pharmacology and Experimental Therapeutics (2014). Accessed Oct 15, 2026